Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2025; 85(05): 507-519
DOI: 10.1055/a-2515-2366
GebFra Science
Review

Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer

Article in several languages: English | deutsch
Diana Lüftner
1   Immanuel Hospital Märkische Schweiz, Buckow, Germany & Medical University of Brandenburg Theodor-Fontane, Rüdersdorf, Germany
,
Hans-Christian Kolberg
2   Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany
,
Andreas D. Hartkopf
3   Department of Gynecology and Obstetrics, Tübingen University Hospital, Tübingen, Germany
,
Tanja N. Fehm
4   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany
5   Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), Düsseldorf, Germany
,
Manfred Welslau
6   Onkologie Aschaffenburg, Aschaffenburg, Germany
,
Volkmar Müller
7   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
,
Florian Schütz
8   Gynäkologie und Geburtshilfe, Diakonissen-Stiftungs-Krankenhaus, Speyer, Germany
,
Peter A. Fasching
9   Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
10   Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
,
Christian Jackisch
11   Evangelische Kliniken Essen Mitte GmbH, Essen, Germany
,
Frederik Marme
12   Universitätsmedizin Mannheim, Frauenklinik, Mannheim, Germany
,
Katharina Keller
9   Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
10   Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
,
Manuel Hörner
9   Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
10   Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
,
Chloë Goossens
9   Department of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
10   Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
,
Erik Belleville
13   ClinSol GmbH & Co. KG, Würzburg, Germany
,
Michael Untch
14   Clinic for Gynecology and Obstetrics, Breast Cancer Center, Gynecologic Oncology Center, Helios Klinikum Berlin Buch, Berlin, Germany
,
Marc Thill
15   Agaplesion Markus Krankenhaus, Department of Gynecology and Gynecological Oncology, Frankfurt am Main, Germany
,
Hans Tesch
16   Oncology Practice at Bethanien Hospital, Frankfurt am Main, Germany
,
Nina Ditsch
17   Department of Gynecology and Obstetrics, University Hospital Augsburg, Augsburg, Germany
,
Julia C. Radosa
18   Department of Gynecology and Obstetrics, Saarland University Hospital, Homburg, Germany
,
Maggie Banys-Paluchowski
19   Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
,
Achim Wöckel
20   Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany
,
Nadia Harbeck
21   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
,
Elmar Stickeler
22   Department of Obstetrics and Gynecology, Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, Düsseldorf), University Hospital of RWTH Aachen, Aachen, Germany
,
Rupert Bartsch
23   Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
,
Bahriye Aktas
24   Department of Gynecology, University of Leipzig Medical Center, Leipzig, Germany
,
Andreas Schneeweiss
25   National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
,
Johannes Ettl
26   Department of Obstetrics and Gynecology and Department of Oncology and Palliative Care, Cancer Center Kempten/Allgäu, Klinikverbund Allgäu gGmbH, Kempten, Germany
,
Florin-Andrei Taran
27   Department of Gynecology and Obstetrics, University Hospital Freiburg, Freiburg, Germany
,
Wolfgang Janni
28   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
,
Rachel Würstlein
21   Breast Center, Department of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany
,
Michael P. Lux
29   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy landscape for patients with advanced stage breast cancer. CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab govitecan have all been shown to provide significant overall survival benefits compared to conventional chemotherapy. Other substances are also showing promising results and hold out the hope that further analysis of the overall survival benefits will be available in the near future. The speed at which studies are now being carried out has markedly increased, and conferences and specialist journals are now constant sources of new information. This review summarizes the most recent publications and conference presentations on the treatment of patients with advanced stage breast cancer.

Keywords

breast cancer - advanced breast cancer - clinical studies - prognosis


Publication History

Received: 20 November 2024

Accepted after revision: 07 December 2024

Article published online:
15 May 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Robson M, Im S-A, Senkus E. et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017; 377: 523-533
    CrossrefPubMedSearch in Google Scholar
  • 2 Litton JK, Rugo HS, Ettl J. et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018; 379: 753-763
    CrossrefPubMedSearch in Google Scholar
  • 3 Turner NC, Telli ML, Rugo HS. et al. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res 2019; 25: 2717-2724
    CrossrefPubMedSearch in Google Scholar
  • 4 Robson ME, Tung N, Conte P. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physicianʼs choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019; 30: 558-566
    CrossrefPubMedSearch in Google Scholar
  • 5 Fasching PA, Hu C, Hart SN. et al. Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer. NPJ Breast Cancer 2024; 10: 57
    CrossrefPubMedSearch in Google Scholar
  • 6 Ettl J, Quek RGW, Lee KH. et al. Quality of life with talazoparib versus physicianʼs choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol 2018; 29: 1939-1947
    CrossrefPubMedSearch in Google Scholar
  • 7 Thill M, Janni W, Albert US. et al. Arbeitsgemeinschaft Gynakologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024. Breast Care (Basel) 2024; 19: 183-191
    CrossrefPubMedSearch in Google Scholar
  • 8 Tung NM, Robson ME, Ventz S. et al. TBCRC048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). J Clin Oncol 2020; 38: 1002
    CrossrefPubMedSearch in Google Scholar
  • 9 Tung NM, Robson ME, Nanda R. et al. TBCRC048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2. J Clin Oncol 2024; 42: 1021-1021
    CrossrefPubMedSearch in Google Scholar
  • 10 Fasching PA, Yadav S, Hu C. et al. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer-Association With Patient and Disease Characteristics and Effect on Prognosis. J Clin Oncol 2021; 39: 1619-1630
    CrossrefPubMedSearch in Google Scholar
  • 11 Hortobagyi GN, Stemmer SM, Burris HA. et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 2022; 386: 942-950
    CrossrefPubMedSearch in Google Scholar
  • 12 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524
    CrossrefPubMedSearch in Google Scholar
  • 13 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316
    CrossrefPubMedSearch in Google Scholar
  • 14 Goetz MP, Toi M, Huober J. et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol 2024; 35: 718-727
    CrossrefPubMedSearch in Google Scholar
  • 15 Engler T, Fasching PA, Luftner D. et al. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT. Geburtshilfe Frauenheilkd 2022; 82: 1055-1067
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Braun M, Stoetzer O, Salat C. et al. Current therapy landscape of advanced HER2 negative breast cancer in pateints in a network of office based internistic oncologists and gynecologic oncologists in Germany. Deutscher Krebskongress 2022; Abstract 306.
    PubMed
  • 17 Hartkopf A. Therapy landscapes and molecular markers, the German PRAEGNANT registry. ESMO Breast Cancer Conference 2022. Accessed November 10, 2022 at: https://oncologypro.esmo.org/meeting-resources/esmo-breast-cancer-congress/therapy-landscapes-and-molecular-markers-the-german-praegnant-registry
    PubMed
  • 18 Bidard FC, Kaklamani VG, Neven P. et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2022; 40: 3246-3256
    CrossrefPubMedSearch in Google Scholar
  • 19 Turner NC, Oliveira M, Howell SJ. et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2023; 388: 2058-2070
    CrossrefPubMedSearch in Google Scholar
  • 20 Andre F, Ciruelos E, Rubovszky G. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929-1940
    CrossrefPubMedSearch in Google Scholar
  • 21 Untch M, Ditsch N, Fasching PA. et al. Discussion of ABC7 Consensus and German Recommendations. Geburtshilfe Frauenheilkd 2024; 84: 431-442
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Würstlein R, Kolberg HC, Hartkopf AD. et al. Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2024; 84: 529-540
    Thieme ConnectPubMedSearch in Google Scholar
  • 23 Cardoso F, Paluch-Shimon S, Schumacher-Wulf E. et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 2024; 76: 103756
    CrossrefPubMedSearch in Google Scholar
  • 24 Kalinsky K, Bianchini G, Hamilton EP. et al. Abemaciclib plus fulvestrant vs. fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. J Clin Oncol 2024; 42: LBA1001
    CrossrefPubMedSearch in Google Scholar
  • 25 Kalinsky K, Accordino MK, Chiuzan C. et al. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. J Clin Oncol 2023; 41: 4004-4013
    CrossrefPubMedSearch in Google Scholar
  • 26 Albanell J, Pérez-García JM, Gil-Gil M. et al. Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. Clin Cancer Res 2023; 29: 67-80
    CrossrefPubMedSearch in Google Scholar
  • 27 Mayer EL, Ren Y, Wagle N. et al. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. J Clin Oncol 2024; 42: 2050-2060
    CrossrefPubMedSearch in Google Scholar
  • 28 Schneeweiss A, Brucker SY, Huebner H. et al. CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs. Geburtshilfe Frauenheilkd 2024; 84: 443-458
    Thieme ConnectPubMedSearch in Google Scholar
  • 29 Turner NC, Ro J, Andre F. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219
    CrossrefPubMedSearch in Google Scholar
  • 30 OʼLeary B, Cutts RJ, Liu Y. et al. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discov 2018; 8: 1390-1403
    CrossrefPubMedSearch in Google Scholar
  • 31 Tolaney SM, Toi M, Neven P. et al. Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. Clin Cancer Res 2022; 28: 1500-1506
    CrossrefPubMedSearch in Google Scholar
  • 32 Andre F, Su F, Solovieff N. et al. Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. J Clin Oncol 2020; 38: 1009
    CrossrefPubMedSearch in Google Scholar
  • 33 Jhaveri K, Im S-A, Saura C. et al. Inavolisib or placebo in c,ombination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis. San Antonio Breast Cancer Symposium; San Antonio, TX: December 5 – 8, 2024; Abstract GS3-13 2023.
    PubMed
  • 34 Juric D, Kalinsky K, Turner NC. et al. First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. J Clin Oncol 2024; 42: 1003
    CrossrefPubMedSearch in Google Scholar
  • 35 Cortes J, Kim SB, Chung WP. et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med 2022; 386: 1143-1154
    CrossrefPubMedSearch in Google Scholar
  • 36 Modi S, Saura C, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020; 382: 610-621
    CrossrefPubMedSearch in Google Scholar
  • 37 Modi S, Jacot W, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387: 9-20
    CrossrefPubMedSearch in Google Scholar
  • 38 Curigliano G, Hu X, Dent RA. et al. Trastuzumab deruxtecan (T-DXd) vs. physicianʼs choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). J Clin Oncol 2024; 42: 1025
    CrossrefPubMedSearch in Google Scholar
  • 39 Venetis K, Crimini E, Sajjadi E. et al. HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Front Mol Biosci 2022; 9: 834651
    CrossrefPubMedSearch in Google Scholar
  • 40 Fitzgibbons PL, Connolly JL. College of American Pathologists (CAP). Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. 2021. Accessed August 15, 2024 at: https://documents.cap.org/documents/Breast.Bmk_1.5.0.1.REL_CAPCP_R.pdf
    PubMed
  • 41 Meric-Bernstam F, Makker V, Oaknin A. et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol 2024; 42: 47-58
    CrossrefPubMedSearch in Google Scholar
  • 42 Li BT, Meric-Bernstam F, Bardia A. et al. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol 2024; 25: 707-719
    CrossrefPubMedSearch in Google Scholar
  • 43 Giordano A, Awan AAA, Bruce JY. et al. Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202. J Clin Oncol 2024; 42: 1005
    CrossrefPubMedSearch in Google Scholar
  • 44 Schmid P, Wysocki PJ, Ma CX. et al. 379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1 L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. Ann Oncol 2023; 34: S337
    CrossrefPubMedSearch in Google Scholar
  • 45 Garrido-Castro AC, Kim SE, Desrosiers J. et al. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. J Clin Oncol 2024; 42: LBA1004
    CrossrefPubMedSearch in Google Scholar
  • 46 Andre F, Hamilton EP, Loi S. et al. Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07). J Clin Oncol 2021; 39: TPS1096
    CrossrefPubMedSearch in Google Scholar
  • 47 Swain SM, Baselga J, Kim SB. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-734
    CrossrefPubMedSearch in Google Scholar
  • 48 Baselga J, Cortes J, Kim SB. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119
    CrossrefPubMedSearch in Google Scholar
  • 49 Thill M, Kolberg-Liedtke C, Albert US. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023. Breast Care (Basel) 2023; 18: 306-315
    CrossrefPubMedSearch in Google Scholar
  • 50 Swain SM, Miles D, Kim SB. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21: 519-530
    CrossrefPubMedSearch in Google Scholar
  • 51 Tolaney SM, Barroso-Sousa R, Jiang Z. et al. 328 TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs. a taxane, trastuzumab and pertuzumab in first-line (1 L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Ann Oncol 2021; 32: S507-S508
    CrossrefPubMedSearch in Google Scholar
  • 52 Andre F, Hamilton EP, Loi S. et al. DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. J Clin Oncol 2024; 42: 1009
    CrossrefPubMedSearch in Google Scholar
  • 53 Muller V, Hein A, Hartkopf AD. et al. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry. Eur J Cancer 2022; 172: 13-21
    CrossrefPubMedSearch in Google Scholar
  • 54 Rohatgi A. WebPlotDigitizer Version: 4.6. Accessed September 01, 2022 at: https://automeris.io/WebPlotDigitizer
    PubMed
  • 55 Muller V, Nabieva N, Haberle L. et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast 2018; 37: 154-160
    CrossrefPubMedSearch in Google Scholar
  • 56 Bardia A, Jhaveri K, Im SA. et al. LBA11 Datopotamab deruxtecan (Dato-DXd) vs. chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. Ann Oncol 2023; 34: S1264-S1265
    CrossrefPubMedSearch in Google Scholar
  • 57 Pernas S, Im S-A, Hattori M. et al. Datopotamab deruxtecan (Dato-DXd) vs. chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study. J Clin Oncol 2024; 42: 1006
    CrossrefPubMedSearch in Google Scholar
  • 58 Xu B, Yin Y, Fan Y. et al. Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. J Clin Oncol 2024; 42: 104
    CrossrefPubMedSearch in Google Scholar